Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › NRSN

NeuroSense Therapeutics

NRSN Rare disease Lead: Phase 2 ★ Read the deep dive → 10 Biotech Distilled articles ↓ 38 filings & releases ↓ Cash $166K (Dec 31, 2025) ↓ 10 verdicts ↓ 3 timing quotes ↓
Neurology Small Molecule

Market cap $3.2M 1.9M shares (vendor count, Nov 7, 2026) × $1.68 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-31

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. PrimeC filingDec 2026PrimeC filing, Dec 2026, notable
  2. NDS Canada filingMar 2027NDS Canada filing, Mar 2027, notable
  3. NRSN listing updateMar 2027NRSN listing update, Mar 2027, routine
  4. PrimeC Ph3 start3Q 2027PrimeC Ph3 start, 3Q 2027, notable
  5. PARAGON trial start3Q 2027PARAGON trial start, 3Q 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Capital (as filed)

Cash
$166K cash and cash equivalents · Dec 31, 2025 (20-F)
Operating cash flow
−$1.9M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
$231K cash per the update of Sep 25, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on NeuroSense Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-11 Avoid NeuroSense Therapeutics (NRSN) — Scientific Deep Dive for PrimeC and Pipeline Products Near-terminal balance sheet, going-concern risk, and the Relyvrio precedent dominate the genuinely interesting ALS biology, making the equity primarily a dilution vehicle until a strategic partnership or Phase-3-sized financing materializes.
  2. 2026-07-22 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - The Canada Card Gets Played Health Canada engagement is real but only one leg of a two-legged stool; without a strategic partnership or Phase-3-sized financing, the equity remains a dilution vehicle despite the modestly de-risked Canadian catalyst.
  3. 2026-07-30 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - The Chasm Gets Papered A live $3.79M ATM at $0.4802 with disclosed dilution, workforce cut to seven employees, and no partner confirm the equity is a dilution vehicle; neither tripwire has been cleared.
  4. 2026-07-31 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - The Reverse Split Goes on the Ballot A special meeting to authorize a 1-for-4 to 1-for-40 reverse split with authorized capital held at 200 million shares signals the split is a prerequisite for a dilutive raise, not a listing fix, and no tripwire has been cleared.
  5. 2026-08-31 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - PARAGON Gets Shrunk Redesigning PARAGON 'substantially smaller and shorter' optimizes for reaching a submission rather than definitively answering whether PrimeC works, and neither the partnership nor financing tripwire has been cleared.
  6. 2026-09-09 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - The Ratio Is 1-for-20 A 1-for-20 reverse split at the middle of the authorized band creates a 105:1 authorized-to-outstanding ratio to enable a dilutive raise, not to fix the underlying balance sheet, and no tripwire has been cleared.
  7. 2026-09-25 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - Paying the Bills in Shares PARAGON slipping to Q3 2027, vendor bills settled in stock consuming 12.8% of the post-split float, 'strategic alternatives' language added, and the $35M MVLS gap unsolved ahead of Tuesday's deadline make the equity increasingly uninvestable.
  8. 2026-10-02 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - The Delisting Letter Arrives A formal Nasdaq delisting determination with a 4.7x market-value gap and a $5M immediate-delisting floor only ~33% below the current price make the listing risk the dominant concern, eclipsing the science.
  9. 2026-10-27 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - Selling the Drug Before the Trial A pre-approval commercial channel with an unnamed equity-paid advisor produces no controlled evidence, may impede PARAGON enrollment, and does nothing to address the Nasdaq delisting process as the stock trades below the $5M immediate-delisting floor.
  10. 2026-11-03 Avoid UPDATE: NeuroSense Therapeutics (NRSN) - Canada Slips to March The Canadian NDS slipping to March 2027 pushes the main catalyst to the edge of the Nasdaq Panel's maximum window while the stock trades at roughly half the $5M immediate-delisting floor, making survival of the listing the dominant risk.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (38)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)